Synthaverse SA GPW:SVE:
SAID ON THURSDAY IT HAS RECEIVED MARKETING AUTHORIZATION FOR ONKO BCG MEDICINAL PRODUCT IN SERBIA
APPLICATION FOR OBTAINING MARKETING AUTHORIZATION WAS SUBMITTED BY CORAPHARM, UNDER THE LICENSE GRANTED BY SYNTHAVERSE
PLANS TO CONTINUE GLOBAL REGULATORY AND COMMERCIAL EXPANSION FOR BCG PRODUCTS
Source text for Workspace:
Further company coverage: